Fig. 10.
Chemical structures of (A) lopinavir and (B) ritonavir, the two components of Kaletra. Kaletra was originally developed to treat HIV‐1 infections and its potency in fighting SARS‐CoV‐2 infections was investigated during the early stages of the COVID‐19 pandemic as a potential protease inhibitor [114].